{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T17:42:51Z","timestamp":1769276571606,"version":"3.49.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006518","name":"UNMC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006518","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["R01CA148706"],"award-info":[{"award-number":["R01CA148706"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.jconrel.2019.07.025","type":"journal-article","created":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T19:54:25Z","timestamp":1563566065000},"page":"231-243","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Nanoparticulate delivery of potent microtubule inhibitor for metastatic melanoma treatment"],"prefix":"10.1016","volume":"309","author":[{"given":"Jitender","family":"Bariwal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virender","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajan Sharma","family":"Bhattarai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9522-4474","authenticated-orcid":false,"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3588-0434","authenticated-orcid":false,"given":"Ram I.","family":"Mahato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2019.07.025_bb0005","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejmech.2014.09.051","article-title":"Recent developments in tubulin polymerization inhibitors: an overview","volume":"87","author":"Kaur","year":"2014","journal-title":"Eur. J. Med. Chem."},{"issue":"10","key":"10.1016\/j.jconrel.2019.07.025_bb0010","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1124\/dmd.110.036616","article-title":"Pharmacokinetic optimization of 4-substituted methoxybenzoyl-aryl-thiazole and 2-aryl-4-benzoyl-imidazole for improving oral bioavailability","volume":"39","author":"Li","year":"2011","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.jconrel.2019.07.025_bb0015","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1158\/0008-5472.CAN-17-0577","article-title":"A potent, metabolically stable tubulin inhibitor targets the colchicine binding site and overcomes taxane resistance","volume":"78","author":"Arnst","year":"2018","journal-title":"Cancer Res."},{"issue":"7041","key":"10.1016\/j.jconrel.2019.07.025_bb0020","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature03566","article-title":"Structural basis for the regulation of tubulin by vinblastine","volume":"435","author":"Gigant","year":"2005","journal-title":"Nature"},{"issue":"33","key":"10.1016\/j.jconrel.2019.07.025_bb0025","doi-asserted-by":"crossref","first-page":"13775","DOI":"10.1073\/pnas.0904223106","article-title":"Variations in the colchicine-binding domain provide insight into the structural switch of tubulin","volume":"106","author":"Dorleans","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6979","key":"10.1016\/j.jconrel.2019.07.025_bb0030","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nature02393","article-title":"Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain","volume":"428","author":"Ravelli","year":"2004","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.jconrel.2019.07.025_bb0035","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1158\/1535-7163.MCT-09-0366","article-title":"Microtubule inhibitors: differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance","volume":"8","author":"Perez","year":"2009","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.jconrel.2019.07.025_bb0040","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1124\/mol.63.2.351","article-title":"Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10)","volume":"63","author":"Chen","year":"2003","journal-title":"Mol. Pharmacol."},{"issue":"5","key":"10.1016\/j.jconrel.2019.07.025_bb0045","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1634\/theoncologist.8-5-411","article-title":"The role of ABC transporters in clinical practice","volume":"8","author":"Leonard","year":"2003","journal-title":"Oncologist"},{"issue":"21","key":"10.1016\/j.jconrel.2019.07.025_bb0050","doi-asserted-by":"crossref","first-page":"8881","DOI":"10.1158\/0008-5472.CAN-08-2037","article-title":"The taccalonolides: microtubule stabilizers that circumvent clinically relevant taxane resistance mechanisms","volume":"68","author":"Risinger","year":"2008","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.jconrel.2019.07.025_bb0055","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/sj.bjc.6605489","article-title":"Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents","volume":"102","author":"Stengel","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2019.07.025_bb0060","first-page":"1","article-title":"Colchicine for acute gout","volume":"8","author":"van Echteld","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.jconrel.2019.07.025_bb0065","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1634\/theoncologist.2010-0190","article-title":"Systematic review of medical treatment in melanoma: current status and future prospects","volume":"16","author":"Garbe","year":"2011","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.jconrel.2019.07.025_bb0070","doi-asserted-by":"crossref","first-page":"250","DOI":"10.6004\/jnccn.2009.0020","article-title":"Melanoma","volume":"7","author":"Coit","year":"2009","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"12","key":"10.1016\/j.jconrel.2019.07.025_bb0075","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S1470-2045(03)01280-4","article-title":"Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials","volume":"4","author":"Eigentler","year":"2003","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.jconrel.2019.07.025_bb0080","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/cncr.21611","article-title":"Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma","volume":"106","author":"Rao","year":"2006","journal-title":"Cancer."},{"issue":"17","key":"10.1016\/j.jconrel.2019.07.025_bb0085","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1200\/JCO.2007.15.7636","article-title":"Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma","volume":"27","author":"Hauschild","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2019.07.025_bb0090","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/1758834015616934","article-title":"Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy","volume":"8","author":"Eroglu","year":"2016","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"1A","key":"10.1016\/j.jconrel.2019.07.025_bb0095","first-page":"61","article-title":"Immunotherapy of melanoma","volume":"22","author":"Lugowska","year":"2018","journal-title":"Contemp. Oncol (Pozn)."},{"key":"10.1016\/j.jconrel.2019.07.025_bb0100","article-title":"Anticancer chemotherapy in teenagers and young adults: managing long term side effects","volume":"354","author":"Ahmad","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.jconrel.2019.07.025_bb0105","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-015-0221-1","article-title":"Resistance to cancer chemotherapy: Failure in drug response from ADME to P-gp","volume":"15","author":"Alfarouk","year":"2015","journal-title":"Cancer Cell Int."},{"issue":"11","key":"10.1016\/j.jconrel.2019.07.025_bb0110","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1158\/1535-7163.MCT-10-0399","article-title":"3rd, Barrett CM, et al. I-387, a novel antimitotic indole, displays a potent in vitro and in vivo antitumor activity with less neurotoxicity","volume":"9","author":"Ahn","year":"2010","journal-title":"Mol. Cancer Ther."},{"issue":"13","key":"10.1016\/j.jconrel.2019.07.025_bb0115","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1021\/jm2003427","article-title":"Design, synthesis, and SAR studies of 4-substituted methoxylbenzoyl-aryl-thiazoles analogues as potent and orally bioavailable anticancer agents","volume":"54","author":"Lu","year":"2011","journal-title":"J. Med. Chem."},{"issue":"16","key":"10.1016\/j.jconrel.2019.07.025_bb0120","doi-asserted-by":"crossref","first-page":"7285","DOI":"10.1021\/jm300564b","article-title":"Discovery of novel 2-aryl-4-benzoyl-imidazole (ABI-III) analogues targeting tubulin polymerization as antiproliferative agents","volume":"55","author":"Chen","year":"2012","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.jconrel.2019.07.025_bb0125","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1021\/jm4001117","article-title":"Discovery of 4-aryl-2-benzoyl-imidazoles as tubulin polymerization inhibitor with potent antiproliferative properties","volume":"56","author":"Xiao","year":"2013","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.jconrel.2019.07.025_bb0130","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/jps.2600791102","article-title":"Drug targeting in cancer chemotherapy: a clinical perspective","volume":"79","author":"Gupta","year":"1990","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2019.07.025_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jare.2018.06.005","article-title":"Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: a review","volume":"15","author":"Hossen","year":"2019","journal-title":"J. Adv. Res."},{"issue":"10","key":"10.1016\/j.jconrel.2019.07.025_bb0140","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1021\/bm100561v","article-title":"Synthesis and characterization of amphiphilic lipopolymers for micellar drug delivery","volume":"11","author":"Li","year":"2010","journal-title":"Biomacromolecules."},{"issue":"9","key":"10.1016\/j.jconrel.2019.07.025_bb0145","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1007\/s11095-009-9903-5","article-title":"3rd, Miller DD, Mahato RI. Micellar delivery of bicalutamide and embelin for treating prostate cancer","volume":"26","author":"Danquah","year":"2009","journal-title":"Pharm. Res."},{"issue":"11","key":"10.1016\/j.jconrel.2019.07.025_bb0150","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1007\/s11095-012-0881-7","article-title":"Formulation and characterization of polyester\/polycarbonate nanoparticles for delivery of a novel microtubule destabilizing agent","volume":"29","author":"Mundra","year":"2012","journal-title":"Pharm. Res."},{"issue":"3","key":"10.1016\/j.jconrel.2019.07.025_bb0155","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s13346-015-0226-2","article-title":"Systemic delivery of nanoparticle formulation of novel tubulin inhibitor for treating metastatic melanoma","volume":"5","author":"Mundra","year":"2015","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2019.07.025_bb0160","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jconrel.2017.01.028","article-title":"Polymer conjugate of a microtubule destabilizer inhibits lung metastatic melanoma","volume":"249","author":"Yang","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2019.07.025_bb0165","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jconrel.2015.10.029","article-title":"Micellar formulation of indocyanine green for phototherapy of melanoma","volume":"220","author":"Mundra","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2019.07.025_bb0170","doi-asserted-by":"crossref","DOI":"10.1124\/jpet.119.256628","article-title":"Polymeric micellar delivery of novel microtubule destabilizer and hedgehog signaling inhibitor for treating chemoresistant prostate cancer","author":"Yang","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"9","key":"10.1016\/j.jconrel.2019.07.025_bb0175","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1021\/acsmedchemlett.5b00208","article-title":"Structural optimization of indole derivatives acting at colchicine binding site as potential anticancer agents","volume":"6","author":"Hwang","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"issue":"6","key":"10.1016\/j.jconrel.2019.07.025_bb0180","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1368-7646(02)00121-8","article-title":"Cell cycle regulatory E3 ubiquitin ligases as anticancer targets","volume":"5","author":"Pray","year":"2002","journal-title":"Drug Resist. Updat."},{"issue":"12","key":"10.1016\/j.jconrel.2019.07.025_bb0185","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1158\/1078-0432.CCR-06-0168","article-title":"R-253 disrupts microtubule networks in multiple tumor cell lines","volume":"12","author":"Gururaja","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"50","key":"10.1016\/j.jconrel.2019.07.025_bb0190","doi-asserted-by":"crossref","first-page":"33533","DOI":"10.1074\/jbc.273.50.33533","article-title":"Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis lesson from an uncleavable mutant","volume":"273","author":"Oliver","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.jconrel.2019.07.025_bb0195","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1515\/CCLM.2002.161","article-title":"Overcoming multidrug resistance in taxane chemotherapy","volume":"40","author":"Geney","year":"2002","journal-title":"Clin. Chem. Lab. Med."},{"issue":"13","key":"10.1016\/j.jconrel.2019.07.025_bb0200","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.2174\/1381612053764706","article-title":"Improving the targeting of tubulin-binding agents: lessons from drug resistance studies","volume":"11","author":"Verrills","year":"2005","journal-title":"Curr. Pharm. Des."},{"issue":"6","key":"10.1016\/j.jconrel.2019.07.025_bb0205","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s00280-015-2903-8","article-title":"Antimitotic drugs in the treatment of cancer","volume":"76","author":"van Vuuren","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"11","key":"10.1016\/j.jconrel.2019.07.025_bb0210","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1007\/s11095-012-0828-z","article-title":"An overview of tubulin inhibitors that interact with the colchicine binding site","volume":"29","author":"Lu","year":"2012","journal-title":"Pharm. Res."},{"issue":"3","key":"10.1016\/j.jconrel.2019.07.025_bb0215","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/med.20242","article-title":"Drugs that target dynamic microtubules: a new molecular perspective","volume":"31","author":"Stanton","year":"2011","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.jconrel.2019.07.025_bb0220","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ejmech.2018.11.070","article-title":"Design, synthesis and biological evaluation of quinoline-indole derivatives as anti-tubulin agents targeting the colchicine binding site","volume":"163","author":"Li","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"24","key":"10.1016\/j.jconrel.2019.07.025_bb0225","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.1111\/bph.12704","article-title":"Movers and shakers: cell cytoskeleton in cancer metastasis","volume":"171","author":"Fife","year":"2014","journal-title":"Br. J. Pharmacol."},{"issue":"42","key":"10.1016\/j.jconrel.2019.07.025_bb0230","doi-asserted-by":"crossref","first-page":"32242","DOI":"10.1074\/jbc.M110.160820","article-title":"Inhibition of cell migration and cell division correlates with distinct effects of microtubule inhibiting drugs","volume":"285","author":"Yang","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"18","key":"10.1016\/j.jconrel.2019.07.025_bb0235","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1007\/s00018-011-0735-1","article-title":"Vimentin in cancer and its potential as a molecular target for cancer therapy","volume":"68","author":"Satelli","year":"2011","journal-title":"Cell. Mol. Life Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2019.07.025_bb0240","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.bbrc.2007.06.036","article-title":"Down-regulation of vimentin expression inhibits carcinoma cell migration and adhesion","volume":"360","author":"McInroy","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"18","key":"10.1016\/j.jconrel.2019.07.025_bb0245","doi-asserted-by":"crossref","first-page":"15966","DOI":"10.18632\/oncotarget.3862","article-title":"Vimentin contributes to epithelial-mesenchymal transition cancer cell mechanics by mediating cytoskeletal organization and focal adhesion maturation","volume":"6","author":"Liu","year":"2015","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.jconrel.2019.07.025_bb0250","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/pros.20581","article-title":"The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines","volume":"67","author":"Takeda","year":"2007","journal-title":"Prostate."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365919304122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365919304122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T18:30:32Z","timestamp":1571855432000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365919304122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":50,"alternative-id":["S0168365919304122"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2019.07.025","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanoparticulate delivery of potent microtubule inhibitor for metastatic melanoma treatment","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2019.07.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}